ENDPOINTS

Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ ...

6 years ago

News Briefing

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

7 years ago

News Briefing

Confo Therapeutics raises €30 million; Waylivra receives approval from EU; endpoint met for Merck's Belsomra in ...

7 years ago

News Briefing

Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

7 years ago

News Briefing

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

7 years ago

Peer Review

Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific

7 years ago

News Briefing

Portola gets EU clearance to market Andexxa under new name; Four biotechs set terms for Nasdaq debut

7 years ago

News Briefing

Peer Review: KSQ woos Beni Wolf from Blueprint with CRISPR platform; AstraZeneca exec jumps to CNS biotech spun out ...

7 years ago

Peer Review

Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch

7 years ago

Financing

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

7 years ago

News Briefing

Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

7 years ago

News Briefing

Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more

7 years ago

News Briefing

Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' special report

7 years ago

Editor's note

Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio ...

7 years ago

News Briefing

Roivant's rare disease shop captures FDA designations; China biotech lands $18M launch round

7 years ago

News Briefing

Takeda touts a landmark head-to-head PhIIIb win over Humira; Allergan's oral CGRP is now under FDA review

7 years ago

News Briefing

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

7 years ago

News Briefing

The drug pricing debate in America reaches a boiling point at #JPM19

7 years ago

Pharma

Kaleido prices $75M IPO well below range; Sage raises $575M ahead of FDA decision

7 years ago

News Briefing

Days after Indivior launches authorized Suboxone generic, Mylan offers its copycat; In crowded CGRP market, Alder ...

7 years ago

News Briefing

Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup

7 years ago

News Briefing

3SBio inks China deal with Boston-based Verseau; Eric Topol calls for digital education in NHS report

7 years ago

News Briefing

Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study

7 years ago

News Briefing

Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo's pexidartinib secures speedy FDA ...

7 years ago

News Briefing

about the author

author articles

Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ ...

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

Confo Therapeutics raises €30 million; Waylivra receives approval from EU; endpoint met for Merck's Belsomra in ...

Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific

Portola gets EU clearance to market Andexxa under new name; Four biotechs set terms for Nasdaq debut

Peer Review: KSQ woos Beni Wolf from Blueprint with CRISPR platform; AstraZeneca exec jumps to CNS biotech spun out ...

Four biotech Nasdaq wannabes outline IPO plans — and don't miss Chi-Med's HKEX pitch

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more

Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' special report

Promedior makes a 'breakthrough' with PhIII IPF drug; NASH focused NGM Biopharma sets terms for IPO; bluebird bio ...

Roivant's rare disease shop captures FDA designations; China biotech lands $18M launch round

Takeda touts a landmark head-to-head PhIIIb win over Humira; Allergan's oral CGRP is now under FDA review

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

The drug pricing debate in America reaches a boiling point at #JPM19

Kaleido prices $75M IPO well below range; Sage raises $575M ahead of FDA decision

Days after Indivior launches authorized Suboxone generic, Mylan offers its copycat; In crowded CGRP market, Alder ...

Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup

3SBio inks China deal with Boston-based Verseau; Eric Topol calls for digital education in NHS report

Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study

Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo's pexidartinib secures speedy FDA ...